Nerolidol Mitigates Colonic Inflammation: An Experimental Study Using both In Vivo and In Vitro Models.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
08 Jul 2020
Historique:
received: 29 05 2020
revised: 01 07 2020
accepted: 02 07 2020
entrez: 12 7 2020
pubmed: 12 7 2020
medline: 12 3 2021
Statut: epublish

Résumé

Nerolidol (NED) is a naturally occurring sesquiterpene alcohol present in various plants with potent anti-inflammatory effects. In the current study, we investigated NED as a putative anti-inflammatory compound in an experimental model of colonic inflammation. C57BL/6J male black mice (C57BL/6J) were administered 3% dextran sodium sulfate (DSS) in drinking water for 7 days to induce colitis. Six groups received either vehicle alone or DSS alone or DSS with oral NED (50, 100, and 150 mg/kg body weight/day by oral gavage) or DSS with sulfasalazine. Disease activity index (DAI), colonic histology, and biochemical parameters were measured. TNF-α-treated HT-29 cells were used as in vitro model of colonic inflammation to study NED (25 µM and 50 µM). NED significantly decreased the DAI and reduced the inflammation-associated changes in colon length as well as macroscopic and microscopic architecture of the colon. Changes in tissue Myeloperoxidase (MPO) concentrations, neutrophil and macrophage mRNA expression (CXCL2 and CCL2), and proinflammatory cytokine content (IL-1β, IL-6, and TNF-α) both at the protein and mRNA level were significantly reduced by NED. The increase in content of the proinflammatory enzymes, COX-2 and iNOS induced by DSS were also significantly inhibited by NED along with tissue nitrate levels. NED promoted Nrf2 nuclear translocation dose dependently. NED significantly increased antioxidant enzymes activity (Superoxide dismutase (SOD) and Catalase (CAT)), Hemeoxygenase-1 (HO-1), and SOD3 mRNA levels. NED treatment in TNF-α-challenged HT-29 cells significantly decreased proinflammatory chemokines (CXCL1, IL-8, CCL2) and COX-2 mRNA levels. NED supplementation attenuates colon inflammation through its potent antioxidant and anti-inflammatory activity both in in vivo and in vitro models of colonic inflammation.

Identifiants

pubmed: 32650602
pii: nu12072032
doi: 10.3390/nu12072032
pmc: PMC7400891
pii:
doi:

Substances chimiques

Anti-Inflammatory Agents 0
Antioxidants 0
Cytokines 0
Inflammation Mediators 0
NF-E2-Related Factor 2 0
Nfe2l2 protein, mouse 0
Phytochemicals 0
Sesquiterpenes 0
Peroxidase EC 1.11.1.7
nerolidol QR6IP857S6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : United Arab Emirates University
ID : grant # 31M384.

Références

Nat Rev Gastroenterol Hepatol. 2016 Jan;13(1):13-27
pubmed: 26627550
Nature. 2007 Jul 26;448(7152):427-34
pubmed: 17653185
J Nat Prod. 2015 May 22;78(5):1160-4
pubmed: 25938459
Prim Care. 2017 Dec;44(4):673-692
pubmed: 29132528
J Exp Bot. 2012 Mar;63(5):1951-67
pubmed: 22162874
J Sci Food Agric. 2018 Sep;98(12):4395-4402
pubmed: 29603275
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Cell Mol Life Sci. 2016 Sep;73(17):3221-47
pubmed: 27100828
EXCLI J. 2017 Aug 29;16:1103-1113
pubmed: 29285007
Indian J Biochem Biophys. 1984 Apr;21(2):130-2
pubmed: 6490072
World J Gastrointest Pharmacol Ther. 2016 Aug 6;7(3):353-60
pubmed: 27602236
BBA Clin. 2015 Nov 05;5:16-24
pubmed: 27051585
Ann N Y Acad Sci. 2017 Aug;1401(1):37-48
pubmed: 28891095
Redox Biol. 2018 Apr;14:154-163
pubmed: 28942193
Phytother Res. 2017 Mar;31(3):459-465
pubmed: 28093813
Med Clin (Barc). 2018 Jul 13;151(1):26-33
pubmed: 29246562
J Pathol. 2003 Sep;201(1):7-16
pubmed: 12950012
Nutrition. 2003 Oct;19(10):837-42
pubmed: 14559317
Curr Drug Targets. 2018;19(7):841-853
pubmed: 29141545
Molecules. 2015 Sep 02;20(9):15989-6003
pubmed: 26364630
Medicine (Baltimore). 2020 Mar;99(10):e18925
pubmed: 32150045
Food Funct. 2019 Jul 17;10(7):4143-4152
pubmed: 31241085
Anal Chim Acta. 2005 Aug 1;546(1):11-21
pubmed: 29569547
Ann Gastroenterol. 2015 Apr-Jun;28(2):210-220
pubmed: 25830661
J Immunol. 2013 Sep 1;191(5):2731-41
pubmed: 23904157
Oxid Med Cell Longev. 2016;2016:3612589
pubmed: 27293512
Lancet. 2017 Apr 29;389(10080):1756-1770
pubmed: 27914657
Nat Prod Commun. 2014 Jun;9(6):869-72
pubmed: 25115103
Inflamm Bowel Dis. 2014 Jun;20(6):1099-109
pubmed: 24691115
J Nutr Biochem. 2015 Jul;26(7):752-60
pubmed: 25841250
Am J Physiol Cell Physiol. 2009 May;296(5):C1133-9
pubmed: 19279235
Nat Rev Immunol. 2014 May;14(5):329-42
pubmed: 24751956
Biomed Pharmacother. 2018 Apr;100:417-425
pubmed: 29471244
Eur J Med Chem. 2019 Dec 1;183:111703
pubmed: 31550661
J Gastroenterol Hepatol. 2008 Dec;23 Suppl 2:S229-33
pubmed: 19120903
World J Gastroenterol. 2014 Jan 7;20(1):91-9
pubmed: 24415861
Toxins (Basel). 2018 Sep 13;10(9):
pubmed: 30216983
Med Res Rev. 2020 May;40(3):823-855
pubmed: 31502681
Gut. 2001 Oct;49(4):526-33
pubmed: 11559650
Food Chem. 2017 Sep 15;231:78-86
pubmed: 28450026
J Ethnopharmacol. 2018 Jan 30;211:17-28
pubmed: 28942135
Int J Biochem Cell Biol. 2006;38(10):1654-61
pubmed: 16713323
J Interferon Cytokine Res. 2009 Jun;29(6):313-26
pubmed: 19441883
BMC Neurosci. 2016 Aug 22;17(1):58
pubmed: 27549180
Immunology. 2004 Dec;113(4):427-37
pubmed: 15554920
Cell Death Differ. 2002 Dec;9(12):1321-33
pubmed: 12478469
Fundam Clin Pharmacol. 2016 Feb;30(1):14-22
pubmed: 26791997
J Clin Biochem Nutr. 2018 Nov;63(3):169-174
pubmed: 30487665
J Pathol. 2003 Sep;201(1):28-36
pubmed: 12950014
Recent Pat Biotechnol. 2018;12(3):158-168
pubmed: 29210667
Oncol Rep. 2010 Dec;24(6):1479-86
pubmed: 21042742
Curr Drug Targets. 2020 May 03;:
pubmed: 32364073
Scand J Gastroenterol. 2001 Aug;36(8):854-64
pubmed: 11495082
Clin Immunol. 2009 Jul;132(1):1-9
pubmed: 19321388
Inflammopharmacology. 2013 Oct;21(5):377-83
pubmed: 22956243
Altern Med Rev. 2003 Aug;8(3):247-83
pubmed: 12946238
Mar Drugs. 2018 Apr 30;16(5):
pubmed: 29710854
Anal Biochem. 1972 Jun;47(2):389-94
pubmed: 4556490
World J Clin Cases. 2020 Jun 6;8(11):2081-2091
pubmed: 32548137
Molecules. 2016 Apr 28;21(5):
pubmed: 27136520

Auteurs

Vishnu Raj (V)

Department of Physiology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain 17666, UAE.

Balaji Venkataraman (B)

Department of Physiology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain 17666, UAE.
Zayed Bin Sultan Center for Health Sciences, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain 17666, UAE.

Saeeda Almarzooqi (S)

Department of Pathology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain 17666, UAE.

Sanjana Chandran (S)

Department of Physiology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain 17666, UAE.

Shreesh K Ojha (SK)

Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain 17666, UAE.

Samir Attoub (S)

Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain 17666, UAE.

Thomas E Adrian (TE)

Department of Basic Medical Sciences, Mohamed Bin Rashid University of Medicine and Health Sciences, Dubai 505055, UAE.

Sandeep B Subramanya (SB)

Department of Physiology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain 17666, UAE.
Zayed Bin Sultan Center for Health Sciences, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain 17666, UAE.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH